Year None202320222021 Mar 30, 2023 Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma Mar 01, 2023 Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Feb 23, 2023 Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock Jan 17, 2023 Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Mar 30, 2023 Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma
Mar 01, 2023 Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Jan 17, 2023 Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium